Senti Biosciences, Inc.

NasdaqCM:SNTI Stock Report

Market Cap: US$9.7m

Senti Biosciences Valuation

Is SNTI undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SNTI when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate SNTI's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate SNTI's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for SNTI?

Key metric: As SNTI is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for SNTI. This is calculated by dividing SNTI's market cap by their current book value.
What is SNTI's PB Ratio?
PB Ratio0.6x
BookUS$15.99m
Market CapUS$9.71m

Price to Book Ratio vs Peers

How does SNTI's PB Ratio compare to its peers?

The above table shows the PB ratio for SNTI vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average1.8x
SNGX Soligenix
1.4x-12.1%US$8.4m
ONVO Organovo Holdings
1.7x-10.7%US$5.4m
BCDA BioCardia
2.9x-13.5%US$7.5m
ENSC Ensysce Biosciences
1.2x102.6%US$11.6m
SNTI Senti Biosciences
0.6xn/aUS$9.7m

Price-To-Book vs Peers: SNTI is good value based on its Price-To-Book Ratio (0.6x) compared to the peer average (1.8x).


Price to Book Ratio vs Industry

How does SNTI's PB Ratio compare vs other companies in the US Biotechs Industry?

60 CompaniesPrice / BookEstimated GrowthMarket Cap
GRAL GRAIL
0.2x35.7%US$550.38m
IMAB I-Mab
0.4x1.8%US$78.16m
ACET Adicet Bio
0.4x6.7%US$75.31m
MGX Metagenomi
0.3x-23.2%US$68.11m
SNTI 0.6xIndustry Avg. 1.9xNo. of Companies82PB01.63.24.86.48+
60 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: SNTI is good value based on its Price-To-Book Ratio (0.6x) compared to the US Biotechs industry average (1.8x).


Price to Book Ratio vs Fair Ratio

What is SNTI's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SNTI PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio0.6x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate SNTI's Price-To-Book Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies